TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 06/15/23

— Application Includes Data from Phase 3 FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (BSC) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colorectal Cancer Takeda ( TSE:4502/NYSE:TAK...

2023-06-12 06:59:39 ET Intellia Therapeutics ( NASDAQ: NTLA ) added ~5% pre-market Monday after announcing new data from its Phase 1/2 trial for its gene editing candidate NTLA-2002 in hereditary angioedema (HAE), a rare genetic disorder characterized by inflammatory attacks. ...

2023-06-07 15:46:56 ET A federal judge in California has certified a class action lawsuit against Eli Lilly ( NYSE: LLY ) and Takeda ( TAK ), claiming that the pharmaceutical giants broke federal racketeering law in marketing the Actos diabetes drug hiding its cancer risks. ...

Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 2-6, 2023, in Chicago, Ill. and the 31st Congress o...

− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023 − NDA Includes Results From the Phase 3 FRESCO-2 and FRESCO Clinical Trials Takeda ( TSE:4502/NYSE:TAK ) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) ( H...

2023-05-24 06:33:55 ET U.K.-based Advanz Pharma signed an agreement to get exclusive rights from Alvotech ( NASDAQ: ALVO ) to commercialize five proposed biosimilars in Europe. Alvotech said it will be responsible for development and commercial supply while Advanz will be...

2023-05-21 12:00:17 ET Developers have increasingly relied on an FDA shortcut to win accelerated drug approvals while their confirmatory trials got delayed at the expense of billions to the government-backed healthcare system, a recent analysis from Bloomberg News indicates. The...

2023-05-19 05:13:23 ET The European Medicines Agency (EMA) has accepted and validated Swedish Orphan Biovitrum's (Sobi) ( OTCPK:BIOVF ) application seeking approval of hemophilia A therapy efanesoctocog alfa. Sobi and Sanofi ( NASDAQ: SNY ) have a collabo...

Submission Based on Favorable Results from the First Phase 3 Randomized, Controlled Trial in Patients with cTTP FDA has Granted TAK-755 Priority Review and Rare Pediatric Disease Designation, as well as Fast Track Designation and Orphan Drug Designation in cTTP Takeda ( ...

2023-05-16 01:29:25 ET Summary GSK's operating income margin in Q1 2023 was 29.35%, showing an increase in the previous quarter and the last year. Vaccine sales were $2,493 million in Q1 2023, up 11.9% year-over-year, mainly due to Fluarix and FluLaval, which regulators approved t...